Stockreport

Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML

Aptose Biosciences, Inc. - Common Shares  (APTO) 
Last aptose biosciences, inc. - common shares earnings: 3/10 04:02 pm Check Earnings Report
US:NASDAQ Investor Relations: aptose.com/investors
PDF TUS+VEN+AZA Triplet Frontline Therapy in Newly Diagnosed AML Patients Now Enrolling at U.S. SitesTUS and TUS+VEN Broadly Active Across AML Populations, with Favorable Sa [Read more]